Medtronic plc
MDT- Exchange
- NYSE
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001613103
In the last 90 days, Medtronic plc insiders filed 0 open-market purchases and 3 sales; 2,151 institutions reported holding it in 13F filings for Q2 2026, worth $86.8B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:42 PM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 3, 2026 | May 21, 2025 | May 23, 2024 | May 25, 2023 | May 26, 2022 |
| Revenue | $36.4B | $33.5B | $32.4B | $31.2B | $31.7B |
| Cost of revenue | $12.7B | $11.6B | $11.2B | $10.7B | $10.1B |
| Research and development | $2.87B | $2.73B | $2.73B | $2.70B | $2.75B |
| Selling, general and administrative | $11.8B | $10.8B | $10.7B | $10.4B | $10.3B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B |
| Interest expense | – | – | $719.0M | $636.0M | $553.0M |
| Income tax | $1.30B | $936.0M | $1.13B | $1.58B | $456.0M |
| Net income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B |
| EPS, basic | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 |
| EPS, diluted | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 |
| Weighted shares, basic | 1.28B | 1.29B | 1.33B | 1.33B | 1.34B |
| Weighted shares, diluted | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B |
| Margins and growth | |||||
| Operating margin | 17.8% | 17.8% | 15.9% | 17.6% | 18.2% |
| Net margin | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% |
| Revenue growth, year over year | +8.4% | +3.6% | +3.6% | −1.4% | +5.2% |
| Net income growth, year over year | +3.0% | +26.8% | −2.2% | −25.4% | +39.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 3, 2026 | May 21, 2025 | May 23, 2024 | May 25, 2023 | May 26, 2022 |
| Cash and equivalents | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B |
| Short-term investments | $7.27B | $6.75B | $6.72B | $6.42B | $6.86B |
| Accounts receivable | $6.64B | $6.51B | $6.13B | $6.00B | $5.55B |
| Inventory | $5.95B | $5.48B | $5.22B | $5.29B | $4.62B |
| Total current assets | $24.8B | $23.8B | $21.9B | $21.7B | $23.1B |
| Property, plant and equipment | $7.42B | $6.84B | $6.13B | $5.57B | $5.41B |
| Goodwill | $42.6B | $41.7B | $41.0B | $41.4B | $40.5B |
| Intangible assets | $10.1B | $11.7B | $13.2B | $14.8B | $15.6B |
| Total assets | $93.0B | $91.7B | $90.0B | $90.9B | $91.0B |
| Accounts payable | $2.64B | $2.45B | $2.41B | $2.66B | $2.28B |
| Short-term debt | $1.79B | $2.87B | $1.09B | $20.0M | $3.74B |
| Total current liabilities | $11.7B | $12.9B | $10.8B | $9.05B | $12.4B |
| Total liabilities | $43.0B | $43.4B | $39.6B | $39.3B | $38.3B |
| Shareholders' equity | $50.1B | $48.3B | $50.4B | $51.7B | $52.7B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Apr 24, 2026 | Apr 25, 2025 | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 3, 2026 | May 21, 2025 | May 23, 2024 | May 25, 2023 | May 26, 2022 |
| Operating cash flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Capital expenditures | $1.90B | $1.86B | $1.59B | $1.46B | $1.37B |
| Free cash flow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B |
| Depreciation and amortization | $2.96B | $2.86B | $2.65B | $2.70B | $2.71B |
| Stock-based compensation | $457.0M | $429.0M | $393.0M | $355.0M | $359.0M |
| Dividends paid | $3.64B | $3.59B | $3.67B | $3.62B | $3.38B |
| Share buybacks | $1.03B | $3.23B | $2.14B | $645.0M | $2.54B |
| Investing cash flow | -$2.93B | -$1.94B | -$2.37B | -$3.49B | -$1.66B |
| Financing cash flow | -$4.75B | -$4.36B | -$4.45B | -$4.96B | -$5.34B |
| Net change in cash | -$269.0M | $934.0M | -$259.0M | -$2.17B | $121.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.3% | 1.3% | 1.2% | 1.1% | 1.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.